Strongbridge Biopharma (NASDAQ:SBBP)’s share price shot up 5.5% on Wednesday . The company traded as high as $5.02 and last traded at $4.63, with a volume of 97,731 shares traded. The stock had previously closed at $4.39.

A number of brokerages recently weighed in on SBBP. Zacks Investment Research upgraded shares of Strongbridge Biopharma from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a report on Wednesday, July 20th. HC Wainwright began coverage on shares of Strongbridge Biopharma in a report on Monday, April 25th. They set a “buy” rating and a $15.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $13.96.

The company’s 50-day moving average is $4.12 and its 200-day moving average is $4.45. The company’s market cap is $98.18 million.

Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Tuesday, May 17th. The company reported ($0.57) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.06. Analysts predict that Strongbridge Biopharma will post ($1.78) EPS for the current year.

Strongbridge Biopharma plc, formerly Cortendo plc, is a development-stage biopharmaceutical company. The Company is engaged in advancing its product candidates through clinical development. The Company is focused on the development, in-licensing, acquisition and eventual commercialization of several complementary products and product candidates within franchises that target rare diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.